LV11823B - PREPARATION FOR RENEWING THE TONNAL SUCCESS OF OLNIC ESTROGENES IN LONG-TERM TREATMENT TREATMENT - Google Patents

PREPARATION FOR RENEWING THE TONNAL SUCCESS OF OLNIC ESTROGENES IN LONG-TERM TREATMENT TREATMENT Download PDF

Info

Publication number
LV11823B
LV11823B LVP-97-30A LV970030A LV11823B LV 11823 B LV11823 B LV 11823B LV 970030 A LV970030 A LV 970030A LV 11823 B LV11823 B LV 11823B
Authority
LV
Latvia
Prior art keywords
preparation
estrogen
gnrh antagonist
gnrh
proliferation
Prior art date
Application number
LVP-97-30A
Other languages
English (en)
Latvian (lv)
Other versions
LV11823A (lv
Inventor
Gary D. Hodgen
Audrey Philips
Original Assignee
The Medical College Of Hampton Roads
Ortho Pharmaceutical Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26959766&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LV11823(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/467,860 external-priority patent/US5658884A/en
Application filed by The Medical College Of Hampton Roads, Ortho Pharmaceutical Corporation filed Critical The Medical College Of Hampton Roads
Publication of LV11823A publication Critical patent/LV11823A/xx
Publication of LV11823B publication Critical patent/LV11823B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
LVP-97-30A 1994-07-22 1997-02-26 PREPARATION FOR RENEWING THE TONNAL SUCCESS OF OLNIC ESTROGENES IN LONG-TERM TREATMENT TREATMENT LV11823B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27959394A 1994-07-22 1994-07-22
US08/467,860 US5658884A (en) 1994-07-22 1995-06-06 Establishment of tonic ovarian estrogen secretion for extended therapeutic regimens
PCT/US1995/008996 WO1996003138A1 (en) 1994-07-22 1995-07-18 Establishment of tonic ovarian estrogen secretion for extended therapeutic regimens

Publications (2)

Publication Number Publication Date
LV11823A LV11823A (lv) 1997-08-20
LV11823B true LV11823B (en) 1998-03-20

Family

ID=26959766

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-97-30A LV11823B (en) 1994-07-22 1997-02-26 PREPARATION FOR RENEWING THE TONNAL SUCCESS OF OLNIC ESTROGENES IN LONG-TERM TREATMENT TREATMENT

Country Status (29)

Country Link
EP (1) EP0769956B1 (xx)
JP (1) JP3138477B2 (xx)
CN (1) CN1137722C (xx)
AP (1) AP775A (xx)
AT (1) ATE190494T1 (xx)
AU (1) AU691952B2 (xx)
BG (1) BG63363B1 (xx)
BR (1) BR9508718A (xx)
CA (1) CA2195745C (xx)
CY (1) CY2228B1 (xx)
CZ (1) CZ291803B6 (xx)
DE (1) DE69515666T2 (xx)
DK (1) DK0769956T3 (xx)
EE (1) EE03515B1 (xx)
ES (1) ES2145286T3 (xx)
FI (1) FI970244A (xx)
GR (1) GR3033590T3 (xx)
HU (1) HU218910B (xx)
IL (1) IL114655A (xx)
IS (1) IS4413A (xx)
LV (1) LV11823B (xx)
MX (1) MX9700574A (xx)
NO (1) NO970257L (xx)
NZ (1) NZ290554A (xx)
OA (1) OA10730A (xx)
PT (1) PT769956E (xx)
RU (1) RU2181598C2 (xx)
SK (1) SK282118B6 (xx)
WO (1) WO1996003138A1 (xx)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8173592B1 (en) 1999-03-31 2012-05-08 Zentaris Ivf Gmbh Method for a programmed controlled ovarian stimulation protocol
UA73956C2 (en) * 1999-09-23 2005-10-17 Zentaris Gmbh Method for therapeutic management of extrauterine proliferation of endometrial tissue, chronic pelvic pain and fallopian tube obstruction due to extrauterine proliferation of endometrial tissue
DE10137174A1 (de) * 2001-07-31 2003-02-13 Zentaris Ag Verwendung von LHRH-Antagonisten in nichtkastrierenden Dosen zur Verbesserung der T-Zellen-vermittelten Immunität
GB0616111D0 (en) * 2006-06-16 2006-09-20 Ardana Bioscience Ltd Agents, methods and uses
EP2095818A1 (en) 2008-02-29 2009-09-02 AEterna Zentaris GmbH Use of LHRH antagonists at non-castrating doses
EP2307040B1 (en) * 2008-05-29 2015-09-09 Isr Immune System Regulation Ab Use of gnrh and sex hormones for treating viral disease, in particular hiv/aids
ES2753539T3 (es) * 2015-05-18 2020-04-13 Nerre Therapeutics Ltd Antagonista del receptor NK-1/NK-3 para el tratamiento de los sofocos
EP3560555A1 (en) * 2018-04-26 2019-10-30 LifeArc A composition for treating one or more estrogen related diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5171835A (en) * 1988-10-21 1992-12-15 The Administrators Of The Tulane Educational Fund LHRH antagonists
US5169932A (en) * 1989-10-30 1992-12-08 The Salk Institute For Biological Studies Gnrh analogs
US5211952A (en) * 1991-04-12 1993-05-18 University Of Southern California Contraceptive methods and formulations for use therein
ZA924811B (en) * 1991-06-28 1993-12-29 Endorecherche Inc Controlled release systems and low dose androgens
US5681817A (en) * 1994-02-04 1997-10-28 The Medical College Of Hampton Roads Treatment of ovarian estrogen dependent conditions
US5407955A (en) * 1994-02-18 1995-04-18 Eli Lilly And Company Methods for lowering serum cholesterol and inhibiting smooth muscle cell proliferation, restenosis, endometriosis, and uterine fibroid disease

Also Published As

Publication number Publication date
CZ291803B6 (cs) 2003-06-18
CN1200674A (zh) 1998-12-02
IL114655A (en) 2005-08-31
CA2195745C (en) 2005-03-29
OA10730A (en) 2001-06-07
JPH10503203A (ja) 1998-03-24
BR9508718A (pt) 1997-12-30
MX9700574A (es) 1997-12-31
HUT77127A (hu) 1998-03-02
WO1996003138A1 (en) 1996-02-08
HU9700046D0 (en) 1997-02-28
FI970244A0 (fi) 1997-01-21
CN1137722C (zh) 2004-02-11
AP9700913A0 (en) 1997-01-31
ES2145286T3 (es) 2000-07-01
CY2228B1 (en) 2003-04-18
EP0769956B1 (en) 2000-03-15
FI970244A (fi) 1997-01-21
DK0769956T3 (da) 2000-06-05
RU2181598C2 (ru) 2002-04-27
LV11823A (lv) 1997-08-20
IL114655A0 (en) 1995-11-27
DE69515666D1 (de) 2000-04-20
EP0769956A4 (en) 1999-03-10
GR3033590T3 (en) 2000-09-29
ATE190494T1 (de) 2000-04-15
JP3138477B2 (ja) 2001-02-26
BG63363B1 (bg) 2001-11-30
AU3132095A (en) 1996-02-22
PT769956E (pt) 2000-07-31
IS4413A (is) 1997-01-14
EE9700208A (et) 1998-02-16
BG101158A (en) 1997-09-30
SK7097A3 (en) 1997-11-05
EE03515B1 (et) 2001-10-15
AP775A (en) 1999-10-28
NZ290554A (en) 2000-08-25
NO970257D0 (no) 1997-01-21
HU218910B (hu) 2000-12-28
EP0769956A1 (en) 1997-05-02
AU691952B2 (en) 1998-05-28
DE69515666T2 (de) 2000-07-06
NO970257L (no) 1997-01-21
CA2195745A1 (en) 1996-02-08
SK282118B6 (sk) 2001-11-06
CZ15097A3 (en) 1997-11-12

Similar Documents

Publication Publication Date Title
EP0785792B1 (en) Treatment of ovarian estrogen dependent conditions
EP0686037B1 (en) Hormone replacement therapy
Maheux et al. Use of intranasal luteinizing hormone-releasing hormone agonist in uterine leiomyomas
US5552394A (en) Low dose oral contraceptives with less breakthrough bleeding and sustained efficacy
CA2195745C (en) Establishment of tonic ovarian estrogen secretion for extended therapeutic regimens
Reichel et al. Goserelin (Zoladex) depot in the treatment of endometriosis
Bygdeman et al. Contraceptive use of antiprogestin
Hodgen Pregnancy prevention by intravaginal delivery of a progesterone antagonist: RU486 tampon for menstrual induction and absorption
US5658884A (en) Establishment of tonic ovarian estrogen secretion for extended therapeutic regimens
Pasquale Rationale for a triphasic oral contraceptive
US5116818A (en) Method and kit for contraception with GnRH-antagonist
Lipitz et al. Suppression with gonadotropin-releasing hormone analogues prior to stimulation with gonadotropins: comparison of three protocols
DANAZOL et al. A. LEMAY and HRPI buserelin protocol 310 study group Endocrinology of Reproduction, Hospital Saint-Francoise D'Assise, Quebec G1L 3L5, Canada; Hoechst-Roussel Pharmaceuticals Inc. Somerville, New Jersey, USA
Reid et al. LHRH agonists and antagonists: therapeutic possibilities for premenstrual syndrome
Lemay et al. Comparison of Buserelin to Danazol Therapy in Endometriosis